EUROAPI entered a collaboration with SpiroChem, a CRO based in Basel, Switzerland specialized in the field of early Chemical Process R&D (route scouting), to offer their customers consolidated CRO-CDMO services. The companies aim to ensure that industrialization constraints for small molecules are integrated from the initial step of drug design, thereby helping to speed the process.
 
Customers will have access to SpiroChem’s expertise in route scouting and EUROAPI’s industrialization strategy to develop the best synthetic routes in line with scale-up feasibility, quality, regulatory, environmental requirements, and economic sustainability, as well as SpiroChem’s early-stage services and EUROAPI’s development and manufacturing capacities.
 
“By adding a renowned CRO partner like SpiroChem to our existing R&D and industrial offering, this fruitful collaboration will strengthen our market position and accelerate our CDMO roadmap,” said Cécile Maupas, Chief CDMO Officer of EUROAPI. “Together with EUROAPI’s production technologies, SpiroChem’s recognized capabilities in route scouting will enable us to provide customers with integrated customized solutions to make their chemical drug development shorter, greener and more cost-efficient.”
 
“Having EUROAPI as a partner brings a substantial value to SpiroChem’s customers who are looking for reliable CDMOs to rapidly and seamlessly scale up the innovative solutions developed by SpiroChem,” said Thomas Fessard, CEO and co-founder of SpiroChem. “Time is of the essence in early CMC2 and we are confident that this collaboration will greatly benefit our customer base, in particular by accelerating the transition from discovery to development for early-stage projects and the biotech segment.”